NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against NowRx, Inc. ("NowRx") (NASDAQ:NOWRX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the […]

Calgary, Alberta–(Newsfile Corp. – January 5, 2026) – SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) (“SuperQ Quantum“, “SuperQ“, or the “Company“), a leader in hybrid quantum-classical orchestration and advanced optimization platforms, is pleased to announce it has signed a formal Memorandum of Understanding (MOU) with Aegis Critical Energy Defence Corp. (CSE: QESS) (OTCQB: QESSF) (FSE:

NEW YORK, NY / ACCESS Newswire / January 5, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sprouts Farmers Market, Inc. ("Sprouts" or "the Company") (NASDAQ:SFM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE) and certain officers.�� The class action, filed in the United States District Court for the Southern District of California, and docketed under 25-cv-03177,

NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE:INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Since commencement of operations through September 30, 2025, Prospect Credit REIT, LLC (“PCRED”), a non-traded real estate credit fund, achieved an annualized total return of 13.35% to investors. Over this period, PCRED's total return performance has been higher than the average total return of 6.28% of the

Prospect Credit REIT Achieves 13.35% Annualized Total Return Versus 6.28% Stanger-Tracked Non-Traded REIT Average Through Q3 2025 GlobeNewswire January 05, 2026 NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Since commencement of operations through September 30, 2025, Prospect Credit REIT, LLC (“PCRED”), a non-traded real estate credit fund, achieved an annualized total return of 13.35%

(NASDAQ:CBIO), CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China Four clinical

(NASDAQ:MOB),(NASDAQ:MOBBW),(AUST:MOB.AX), New customer engagement supports Mobilicom's expansion across the Middle East region, with live prototype demonstration planned at UMEX Abu Dhabi in January 2026 Palo Alto, California, Jan. 05, 2026 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced

(NASDAQ:OKYO), Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment